Concourse Financial Group Securities, Inc. Alx Oncology Holdings Inc Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$1.81 - $8.13 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$5.84 - $17.56 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$10.95 - $16.79 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$4.81 - $15.38 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$4.19 - $7.35 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$4.19 - $7.35 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$4.37 - $9.56 $0 - $0
Q1 2023 May 15, 2023	BUY	$4.52 - $11.71 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$9.51 - $12.95 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$8.23 - $15.14 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$5.89 - $19.46 $0 - $0
Q1 2022 May 09, 2022	BUY	$13.65 - $22.06 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$21.49 - $74.4 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$52.51 - $80.91 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$52.2 - $75.23 $0 - $0
Q1 2021 May 13, 2021	BUY	$62.84 - $87.68 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$34.11 - $112.26 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$29.36 - $47.1 $0 - $0

Others Institutions Holding ALXO

# of Institutions

101

Shares Held

39.7M

Call Options Held

134K

Put Options Held

17.4K

Ven Bio Partners LLC San Francisco, CA

9.7M
Shares

$17.8 Million
14.51% of portfolio
Tang Capital Management LLC San Diego, CA

4.2M
Shares

$7.69 Million
0.65% of portfolio
Vivo Capital, LLC Palo Alto, CA

4.03M
Shares

$7.38 Million
1.07% of portfolio
Redmile Group, LLC San Francisco, CA

3.84M
Shares

$7.02 Million
0.46% of portfolio
Black Rock Inc. New York, NY

2.69M
Shares

$4.92 Million
0.0% of portfolio

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $74.6M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account